Skip to content
TrialScanner

NCT05177770

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2TerminatedCHRSLeadRCUSCollaborator

Registry record

Lead sponsor
Coherus Oncology, Inc.
Conditions
Metastatic Castration-resistant Prostate Cancer; Prostate Cancer
Primary completion
Apr 5, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05177770 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05177770: Study of SRF617 With AB928... | TrialScanner